Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Acute Fever Clear all

Conditions: Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia, Adult Burkitt Lymphoma, Adult Diffuse Large Cell Lymphoma, Adult Diffuse Mixed Cell Lymphoma, Adult Diffuse Small Cleaved Cell Lymphoma, Adult Hodgkin Lymphoma, Adult Immunoblastic Large Cell Lymphoma, Adult Lymphoblastic Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Breast Cancer, Chronic Eosinophilic Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Cutaneous T-cell Non-Hodgkin Lymphoma, Disseminated Neuroblastoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3 Follicular Lymphoma, Malignant Testicular Germ Cell Tumor, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Multiple Myeloma, Mycosis Fungoides/Sezary Syndrome, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neutropenia, Nodal Marginal Zone B-cell Lymphoma, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Plasma Cell Neoplasm, Poor Prognosis Metastatic Gestational Trophoblastic Tumor, Primary Myelofibrosis, Prolymphocytic Leukemia, Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma
Interventions: cefepime hydrochloride; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Leukemia, Lymphocytic, Leukemia, Myeloid
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Stanford, California

Conditions: Acute Fever
Interventions: Not listed
Lead sponsor: BioFire Diagnostics, LLC; Industry
Eligibility: Up to 3 Years
Enrollment: 1,514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Atlanta, Georgia • Indianapolis, Indiana • Kansas City, Missouri + 3 more

Conditions: Infection
Interventions: Ibuprofen, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 5
States / cities: Cypress, California • Westlake Village, California • Omaha, Nebraska + 2 more

Conditions: Respiratory Infection, Respiratory Infections in Old Age, Respiratory Infection Virus, Respiratory Infection Bacterial
Interventions: MeMed BV® test; Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Long COVID
Interventions: Heat therapy, Sham Control, Walking; Behavioral
Lead sponsor: University of Nebraska; Other
Eligibility: 50 Years to 90 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Infections, Urinary Tract
Interventions: GSK2251052, imipenem-cilastatin, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Los Angeles, California • Council Bluffs, Iowa • Topeka, Kansas + 1 more

Conditions: Pain, Fever
Interventions: IV Acetaminophen; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 29 Days to 16 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 5
States / cities: Stanford, California • Ann Arbor, Michigan • Durham, North Carolina + 2 more

Conditions: Acute Urinary Tract Infection, Urinary Tract Infection
Interventions: Placebo, Dexamethasone; Drug
Lead sponsor: Nader Shaikh; Other
Eligibility: 2 Months to 6 Years
Enrollment: 546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Columbus, Ohio • Pittsburgh, Pennsylvania + 3 more

Conditions: Back Strain, Neck Strain
Interventions: Heat, Cold; Other
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Cancer
Interventions: caspofungin acetate, liposomal amphotericin B; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Myelodysplastic Syndromes, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: recombinant human mannose-binding lectin; Biological
Lead sponsor: Enzon Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 3
States / cities: Orange, California • Washington D.C., District of Columbia • Philadelphia, Pennsylvania

Conditions: Long COVID
Interventions: whole body hyperthermia; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Subarachnoid Hemorrhage, Subdural Hematoma, Traumatic Brain Injury, Ischemic Stroke, Fever, Intracerebral Hemorrhage
Interventions: Bromocriptine 5 MG, Acetaminophen 650 MG; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 100 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Acute Pain, Fever
Interventions: IV Acetaminophen; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 14
States / cities: Arcadia, California • Glendale, California • Laguna Hills, California + 10 more

Conditions: Bone Marrow Suppression, Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: piperacillin sodium, piperacillin-tazobactam, tazobactam sodium, vancomycin; Drug
Lead sponsor: European Organisation for Research and Treatment of Cancer - EORTC; Network
Eligibility: 2 Years and older
Enrollment: 859 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 2
States / cities: Baltimore, Maryland • Boston, Massachusetts

Conditions: Acute Ebola Virus Disease
Interventions: INTERCEPT Plasma; Biological
Lead sponsor: Cerus Corporation; Industry
Eligibility: Not listed
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 2
States / cities: Atlanta, Georgia • Omaha, Nebraska

Conditions: Ebola Virus Disease, Marburg Virus Disease
Interventions: cAd3-Marburg, cAd3-EBO-S; Biological
Lead sponsor: Albert B. Sabin Vaccine Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Autoimmune Encephalitis, Celiac Disease, Celiac Disease in Children, Chronic Lyme Disease, Post-treatment Lyme Disease Syndrome, Crohn's Disease, Dysautonomia, Anorexia Nervosa, Bulimia Nervosa, ARFID, Avoidant / Restrictive Food Intake Disorder, Ehlers Danlos Syndrome, Endometriosis, Fibromyalgia (FM), Long COVID, Lupus, Migraines, Mast Cell Activation Syndrome, Multiple Sclerosis, Myalgic Encephalomyelitis (ME), Myasthenia Gravis, Generalized, Myasthenia Gravis in Children, Narcolepsy, Obsessive Compulsive Disorder (OCD), PANDAS, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), POTS - Postural Orthostatic Tachycardia Syndrome, General Anxiety Disorder, Social Anxiety Disorder, PTSD - Post Traumatic Stress Disorder, Psoriasis, Traumatic Brain Injury, Tourette's Syndrome, Inflammatory Bowel Disease (IBD), Autoimmune Diseases, Neurological Diseases or Conditions, Psychiatric Disorder, Sjogren's Syndrome, Ulcerative Colitis and Crohn's Disease
Interventions: Not listed
Lead sponsor: Brain Inflammation Collaborative; Other
Eligibility: 2 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Delafield, Wisconsin

Conditions: Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Neutropenia, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: cefepime hydrochloride, levofloxacin; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Fever, Sweats, and Hot Flashes, Infection, Kidney Cancer, Leukemia, Lymphoma, Neuroblastoma, Neutropenia, Sarcoma
Interventions: caspofungin acetate; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland + 1 more

Conditions: Conditions, Infections, Heart Failure, Renal and Urinary Disorders, Diabetes, Hypertension, Fever, Bronchitis, Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Digital Care Solution as supportive personalized care, Traditional Hospital Level Care; Other
Lead sponsor: OSF Healthcare System; Other
Eligibility: 18 Years and older
Enrollment: 9,654 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Peoria, Illinois

Conditions: Acute Bacterial Infections, Acute Viral Infections
Interventions: Not listed
Lead sponsor: The Plasma Source; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Southampton, Pennsylvania

Conditions: Patient Compliance, Medication Adherence, Medication Non-Adherence
Interventions: Information prescriptions; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 3,940 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Baltimore, Maryland • Columbia, Maryland

Search by objective public record fields.

Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia

Biomarker To Evaluate Protein Profiles of Neutropenic Fever/Infection With Acute or Chronic Leukemias

Pilot Evaluation of the FilmArray® Febrile Infant (FI) Panel

Study Evaluating The Efficacy Of A Novel Ibuprofen Formulation On Fever In Patients With An Uncomplicated Acute Infection

MeMed BV® Test Evaluation in Adult Emergency Department Patients

Heat thErapy And mobiLity in COVID-19 Survivors

GSK2251052 in Complicated Urinary Tract Infection

Safety and Pharmacokinetic (PK) Study of Intravenous (IV) Acetaminophen Administration in Pediatric Inpatients

Corticosteroids for Children With Febrile Urinary Tract Infections

Heat Versus Ice in the Acute Management of Neck and Back Strain Injuries

Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment

Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia

Sauna for Long Covid

Efficacy of Bromocriptine For Fever Reduction in Acute Neurologic Injury

Safety and Efficacy of Intravenous Acetaminophen (IV APAP) in Adult Inpatients

Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count

A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia

Caspofungin Acetate in Treating Children With Fever and Neutropenia

Analysis of the Virtual Acute Care at Home Experience

300 Antibody Diagnostic Test Kit

Impact of Information Prescriptions on Medication Adherence in Emergency Department (ED) Patients